WO2001010454B1 - Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection - Google Patents

Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection

Info

Publication number
WO2001010454B1
WO2001010454B1 PCT/US2000/021462 US0021462W WO0110454B1 WO 2001010454 B1 WO2001010454 B1 WO 2001010454B1 US 0021462 W US0021462 W US 0021462W WO 0110454 B1 WO0110454 B1 WO 0110454B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
compounds
inhibitor compounds
reverse transcriptase
ribonucleotide reductase
Prior art date
Application number
PCT/US2000/021462
Other languages
French (fr)
Other versions
WO2001010454A3 (en
WO2001010454A9 (en
WO2001010454A2 (en
Inventor
Vassilios L Avramis
Lewis Cohen
Original Assignee
Aventis Pharm Prod Inc
Vassilios L Avramis
Lewis Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/370,390 external-priority patent/US6689762B1/en
Application filed by Aventis Pharm Prod Inc, Vassilios L Avramis, Lewis Cohen filed Critical Aventis Pharm Prod Inc
Priority to CA002346063A priority Critical patent/CA2346063A1/en
Priority to JP2001514970A priority patent/JP2003506409A/en
Priority to AU68944/00A priority patent/AU6894400A/en
Priority to EP00957306A priority patent/EP1143990A3/en
Publication of WO2001010454A2 publication Critical patent/WO2001010454A2/en
Publication of WO2001010454A3 publication Critical patent/WO2001010454A3/en
Priority to HK02102802.2A priority patent/HK1041444A1/en
Publication of WO2001010454B1 publication Critical patent/WO2001010454B1/en
Publication of WO2001010454A9 publication Critical patent/WO2001010454A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Method of inhibiting or treating Human Immunodeficiency Virus (HIV) infection, comprising administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a PEG-ASNase compound or asparaginase, and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HIV reverse transcriptase inhibitor compounds.

Claims

68AMENDED CLAIMS[received by the International Bureau on 06 June 2002 (06.06.02); original claims 4 to 8, 10 to 12, 15 and 16 amended; remaining claims unchanged (4 pages)]
1. A method of inhibiting or treating Human Immunodeficiency Virus (HIV) infection, comprising administering to a patient, in need thereof, a therapeutically effective amount of a composition comprising a PEG-ASNase compound or a pharmaceutically acceptable salt thereof, and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonncleotide reductase inhibitor compounds and HIV reverse transcriptase inhibitor compounds or a pharmaceutically acceptable salt thereof.
2, A method according to claim 1 wherein at least one compound is a protease inhibitor compound.
3. A metiiod according to claim 1 wherein at least one compound is a ribo icicoride reductase inhibitor compound.
4. A method according to claim 1 wherein at least one compound is an HIV reverse transcriptase inhibitor compound.
5. A method according to claim 1 wherein the protease inhibitor compound is selected from Saquinovir, Nelfmavir, Indinavir, Eπdinovere, Ritonavir, Crixivaπ, Viracept, Norvir, aπ VX-478.
6. A method according to claim 3 wherein the ribonucleotide reductase inhibitor compounds arc selected from Hydroxyurca (HU), BW- 348US7, 3-amiπopyridine-2- carboxaldehydc thiosemicarbazone (3-AP) Amidox (VF 236; NSC-343341 ; N,3,4- trihydroxybenzenecarboximida ide), BILD 1257 (2-ben2yl-3-pbenyIpropionyl-L-(N- mcLhyl)valyl-L-3-(me±yl)valyl-L-(N4,N4-tetramelhylcπe)asparaginyl-L-(3,3- tetramethylene)asρarty1-L-(4-methyl)leucine), BILD 1357 (2-benzyl-3-ρhenylpropionyl-L- (N-methyl)valyl-L-3-(me l)valyl-L-( 4,N4-tetrame lene)asparaginyl-L-(3,3- tetramethylene)asparttc acid l-[l(R)-ethyl-2,2-dimethyIpropylaτnide])5 BILD 1633, BILD 733 (3-phenylpropionyl-L-(N- ethyI)vaIyl-L-[3-methyl)vaIyl-L-[3-(pyrrolidin-]- ylcarbonyI)]alanyl--L.(1-carboxycycIoρeniyl)glycyl-L-(4-methyl)leucinol), BILD 1263 (2- benzyl-3-phenylpropionyi-L-(N-methyI)valyl-L'3-(mcthy1)valyl-L-(N4,N4- tetramethylene)asparaginyl-L-(3,3-tetraιne ltnιe)aspaιtyl-L-(4-memyI)leucinol) (l-[l(S)-[5(S)-[3-[(aU^is)-2,6-dimethylcyclohexyl]ureido]-2(S)-(3,3-dimethyl-2-oxobutyl)- 6,6-dimethyl-4-oxoheρtanoylaπώιo]- 1-[1 (R)-ethyI-2,2- 69 dimethylpropylcarbamol]methyl]cyclopentaπecarboxylic acid]), CI-F-araA (2-chloro-9-(2- dcoxy-2-fluoro-bcta-D-arabinofuιariosyl)adenine, DAH -aspaτric-beta-hydroxaτnate), DDFC (2'-deoxy-2\2'-difluorocytidinc),Didox (VF 147; NSC 324360; N,3,4- trihydroxybenzamide), Eurd (3'-Ethynyluι:idiπe),GTI 2040, GΗ 2501,IMHAG (1- isoquinoIylmethane-N-hydroxy-N'-aminoguanine), LY 207702 (2',2,-difluoro-2'- deoxyribo ranosyl-2,6-djaminopurine), LY 295501 (N-[[3,4- dichloroρhenyl)aπuπo]carbonyl]2,3 ihydro-5-benzofuransulfonaπιidc), MDL 101731 (FMdC; KW 2331; (2E)-2'-deoxy-2'-(fluoromcthylene)cytidine), Parabactin Sulofenur (LY 186641; N-t[(4-cWorophenyl)aniino]carbonylJ-2,3-dihydro-lH-indene-5- sulfonamide), TAS 106 (Ecyd; 3'-ethynylcytidine),TrJapinc (OCX 191; OCX 0191), Trimidox (VF 233; N,3-4,5-tetrahydroxybcnzene carboximidamide) and compounds of formula 1
Figure imgf000003_0001
wherein
Rl is alkyl, alkenyl, alkynyl or an electron withdrawing group; and E2 is alkyl, alkenyl, alkynyl; or a pharmaceutically acceptable salt thereof, an N-oxidc thereof, a solvatc thereof, an acid bioisostere thereof, or pτodnιg thereof.
7. A method according to claim 6 wherein the ribonucleotide reductase inhibitor compound is a compound of formula T.
8. A method according to claim 7 wherein the ribonucleotide reductase compound is a compound of formula 1 wherein Rl is lower alkyl or a halogen group; and
R2 is lower alkyl; or a pharmaceutically acceptable salt thereof, an N-oxide thereof, a solvatc thereof, an acid bioisostere thereof, or prodiug thereof. 70
9. A method according to claim 6 wherein the ribonucleotide reductase inhibitor compound of formula I is MISID.
10. A method according to claim 4 wherein the HIV reverse transcriptase inhibitor compound is selected from A2T (Retrovir, zidovudine) ddl (Videx, didanosine) ddC (Hivid, zalcitabine), d4T (Zerit, stavudine) and 3TC (Epivir, lamivudine).
11. A method according to claim 1 wherein said compounds are administered concurrently.
12. A method according to claim 1 wherein said compounds are administered sequentially.
13. A method of inhibiting the production, or limiting the spread, of HTV comprising the step of exposing a cell population infected with HTV to an effective amount of PEG-ASNase compound and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HTV reverse transcriptase inhibitor compounds.
14. A method according to claim 1 wherein the compounds administered comprise a synergistically effective combination of a PEG-ASNase compound and at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HIV reverse transcriptase inhibitor compounds,
15. A pharmaceutical composition comprising a PEG-ASNase compound, and one or more compounds selected from the group consisting of a protease inhibitor compound, a HTV reverse transcriptase inhibitor compound, or a ribonucleotide reductase inhibitor compound, and a pharmaceutically acceptable carrier.
16. A pharmaceutical kit for treating or inhibiting a physiological condition associated with HTV, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a PEG-ASNase compound and at least another of said containers contains one or more compounds selected from the group consisting of a protease inhibitor compound, a HTV reverse transcriptase inhibitor compound and a ribonucleotide reductase inhibitor compound, and said containers optionally contain a pharmaceutical carrier. 71
17. A method of inhibiting or treating Human Immunodeficiency Virus (HTV) infection, comprising administering to a patient, in need thereof, a iherapeutieally effective amount of asparaginase or a pharmaceutically acceptable salt thereof, and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HTV reverse transcriptase inhibitor compounds or a pharmaceutically acceptable salt thereof.
72
STATEMENT UNDER ARTICLE 19(1)
The accompanying amendment revises foπner claims 4 to 8, 10 to 12, 15 and 16, to correct for typographical errors made in the originally filed claims.
PCT/US2000/021462 1999-08-06 2000-08-07 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection WO2001010454A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002346063A CA2346063A1 (en) 1999-08-06 2000-08-07 Composition and methods for treatment of hiv infection
JP2001514970A JP2003506409A (en) 1999-08-06 2000-08-07 Compositions and methods for treating HIV infection
AU68944/00A AU6894400A (en) 1999-08-06 2000-08-07 Composition and methods for treatment of HIV infection
EP00957306A EP1143990A3 (en) 1999-08-06 2000-08-07 Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections
HK02102802.2A HK1041444A1 (en) 1999-08-06 2002-04-13 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/370,390 US6689762B1 (en) 1998-02-09 1999-08-06 Composition and methods for treatment of HIV infection
US09/370,390 1999-08-06

Publications (4)

Publication Number Publication Date
WO2001010454A2 WO2001010454A2 (en) 2001-02-15
WO2001010454A3 WO2001010454A3 (en) 2002-01-24
WO2001010454B1 true WO2001010454B1 (en) 2002-07-11
WO2001010454A9 WO2001010454A9 (en) 2002-11-07

Family

ID=23459436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/021462 WO2001010454A2 (en) 1999-08-06 2000-08-07 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection

Country Status (7)

Country Link
EP (1) EP1143990A3 (en)
JP (1) JP2003506409A (en)
AU (1) AU6894400A (en)
CA (1) CA2346063A1 (en)
HK (1) HK1041444A1 (en)
WO (1) WO2001010454A2 (en)
ZA (1) ZA200102506B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100544718C (en) * 2001-04-20 2009-09-30 维奥恩药品公司 The purposes of chemical compound in the preparation antiviral agent
EP1744761A4 (en) * 2004-04-28 2010-01-13 Molecules For Health Inc Methods for treating or preventing restenosis and other vascular proliferative disorders
EP2030615A3 (en) 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US9556216B2 (en) 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
PL3466934T3 (en) * 2016-05-31 2024-06-10 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds or salt thereof as ribonucleotide reductase inhibitors for treating cancer
CN111386260B (en) * 2017-11-29 2024-04-30 大鹏药品工业株式会社 Sulfonamide compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2600256B1 (en) * 1986-06-19 1988-09-16 Inst Nat Sante Rech Med DRUG AND DRUG COMPOSITION FOR THE TREATMENT OF TUMORS AND FOR THE TREATMENT OF VIRUS-INFECTIOUS DISEASES
ATE265226T1 (en) * 1997-06-09 2004-05-15 Los Angeles Childrens Hospital USE OF WOLINELLA SUCCINOGENES ASPARAGINASE FOR THE TREATMENT OF ASPARAGINE-DEPENDENT DISEASES
DE69909747T2 (en) * 1998-02-09 2004-04-15 Enzon Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS

Also Published As

Publication number Publication date
WO2001010454A3 (en) 2002-01-24
HK1041444A1 (en) 2002-07-12
WO2001010454A9 (en) 2002-11-07
AU6894400A (en) 2001-03-05
JP2003506409A (en) 2003-02-18
EP1143990A2 (en) 2001-10-17
ZA200102506B (en) 2002-03-27
EP1143990A3 (en) 2002-03-27
WO2001010454A2 (en) 2001-02-15
CA2346063A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
RU2145235C1 (en) Human interferon-containing therapeutic composition, interferon-base pharmaceutical preparation (variants)
RU2440822C2 (en) Methods and pharmaceutical compositions for treatment and prevention of hepatitis c infection
DE60018273T2 (en) PEGYLATED INTERFERON ALPHA IN COMBINATION WITH A CCR5 ANTAGONIST FOR AN HIV THERAPY
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
FI893783A (en) A process for the preparation of a pharmaceutical preparation for the treatment of diabetes mellitus
WO2001010454B1 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
JPS62246520A (en) Prevention and reversal for cataract and ophthalmic composition
JPH1017466A (en) Absorption promoter for intestinal juice
ES2203072T3 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS.
JP2002502826A5 (en)
KR100484695B1 (en) Pharmaceutical Compositions
WO1997045127A1 (en) Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
US6689762B1 (en) Composition and methods for treatment of HIV infection
BRPI0415322A (en) antiretroviral pharmaceutical composition, process for the preparation of an antiretroviral pharmaceutical composition, method for reducing the burden of pill consumption for a patient, method for increasing lamivudine and zidovudine half-life while not affecting nevirapine half-life
US11278514B2 (en) Composition compromising dunnione as effective ingredient for prevention or alleviation of hair loss
Schiedermayer Christmas on the AIDS Ward
James D4T: new clinical data confirms benefit
JP2005035913A (en) Remedy against virus having plus strand rna in genetic information
Smith HIV treatment options
Miller New ways to take old drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000957306

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/02506

Country of ref document: ZA

Ref document number: 200102506

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2346063

Country of ref document: CA

Ref country code: CA

Ref document number: 2346063

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 514970

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 68944/00

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2000957306

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWW Wipo information: withdrawn in national office

Ref document number: 2000957306

Country of ref document: EP